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Abstract
Plk1 plays a pivotal role in cell proliferation and is considered an attractive target for anti-cancer
therapy. The noncatalytic polo-box domain (PBD) of Plk1 forms a phosphoepitope-binding
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module for protein-protein interaction. Here, we report the identification of minimal
phosphopeptides that specifically interacted with the PBD of Plk1, but not the two closely-related
Plk2 and Plk3. Comparative binding studies and analyses of crystal structures of the Plk1 PBD in
complex with the minimal phosphopeptides revealed that the C-terminal SpT dipeptide functions
as a high affinity anchor, whereas the N-terminal residues are critical for providing both
specificity and affinity to the interaction. Inhibition of the Plk1 PBD by phospho-Thr mimetic
peptides was sufficient to induce mitotic arrest and apoptotic cell death. Thus, the mode of the
minimal peptide and PBD interaction may provide a template for designing anti-Plk1 therapeutic
agents.
Keywords
Plk1; polo kinase; polo-box domain; PBIP1; mitosis; crystal structure
Polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases
that play critical roles in cell proliferation (reviewed in refs 1,2). Plks are characterized by
the presence of a highly conserved C-terminal polo-box domain (PBD) composed of two
structurally-related PB1 (residues 411-489 in Plk1) and PB2 (residues 511-592) motifs
(reviewed in ref 3). Multiple forms of Plks, designated Plk1, Plk2/Snk, Plk3/Prk/Fnk, and
Plk4/Sak, exist in mammals. Plk4 is the most distantly related member of the Plk subfamily
and one of the two Plk4 variants, Sak-a, contains only the PB1 motif. Among the Plks, Plk1
has been studied most extensively because of its ability to override cellular checkpoints and
induce genetic instability, leading to oncogenic transformation of human cells (reviewed in
refs 4,5). Not surprisingly, Plk1 is overexpressed in a broad spectrum of human cancers.
Furthermore, interference with Plk1 function induces apoptotic cell death in most tumor
cells, but not in normal cells, and reduces tumor growth in mouse xenograft models
(reviewed in ref 5), suggesting that Plk1 can be targeted for therapeutic intervention against
human cancers. In contrast to the role of Plk1 in cell proliferation and tumorigenesis, the two
most closely-related kinases, Plk2 and Plk3, appear to play a role in checkpoint-mediated
cell cycle arrest to ensure genetic stability and prevent oncogenic transformation6,7. Thus,
specific inhibition of Plk1, but not Plk2 or Plk3, is critically important for anti-Plk1 cancer
therapy.
The PBD of Plk1 plays a critical role in proper subcellular localization and mitotic functions
of Plk18–10 by interacting with phosphorylated Ser/Thr peptides with the invariable Ser
residue at the − 1 position (S-p-S/T motif)11. Crystal structures of the Plk1 PBD in complex
with artificial phosphopeptides optimized for PBD binding have revealed that the PB1 and
PB2 motifs have identical β6α folds and form a hetero-dimeric phosphopeptide-binding
module12,13. The phosphopeptide binds to a cleft formed between PB1 and PB2 and
interacts with key amino acid residues from both polo-boxes. His538 and Lys540 from PB2
are pivotal for electrostatic interactions with the negatively charged phosphate group of
phospho-Ser/Thr residue, whereas Trp414 from PB1 is critical for the selection of Ser at the
− 1 position by engaging in two hydrogen bonding interactions and van der Waals
interactions with the Ser-1 residue12,13. However, additional elements required for
achieving a highly specific interaction between human Plk1 and its binding targets remain
elusive. In this study, we took multifaceted approaches to determine critical elements
required for the interaction. Our results provided here may shed new insights into the
development of anti-Plk1 therapeutic agents.
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RESULTS
Identification of minimal p-T78 peptides for Plk1 PBD binding
PBIP1/MLF1IP/KLIP1/CENP-50/CENP-U (PBIP1 hereafter) was isolated as a PBD-
interacting protein critical for centromeric localization of Plk114 and proper chromosome
segregation14–17. Further investigation on the Plk1-PBIP1 interaction shows that the PBD
of Plk1 binds to the T78 region of PBIP1 in a phospho-dependent manner14. To better
understand the binding nature of this interaction, we synthesized various p-T78 peptides for
in vitro binding analyses. A bead-immobilized 10-mer or 14-mer p-T78 peptide, but not the
respective non-phospho forms, precipitated Plk1 from mitotic HeLa cells as the major
binding protein (Supplementary Fig. 1a). To determine a minimal sequence of the T78 motif
required for the interaction, we carried out systematic deletions from the 10-mer p-T78
peptide (PLHSpTAIYAD) and tested the ability of various resulting peptides
(Supplementary Table 1) to bind to Plk1. To our surprise, removal of all the amino acid
residues C-terminal to the p-T78 residue did not diminish the level of Plk1 binding (Fig. 1a,
left), suggesting that the residues after p-T78 are dispensable for PBD binding. Further N-
terminal deletion analyses of PLHSpT showed that LHSpT lacking the N-terminal Pro
possessed a greatly diminished binding affinity to Plk1, while HSpT lacking both the Pro
and Leu residues did not exhibit any detectable level of binding (Fig. 1a, right). These
results suggest that PLHSpT binds to Plk1 with high affinity and that, besides the SpT
dipeptide, the N-terminal Pro-Leu motif is required to provide an additional level of affinity
to the PBD.
To eliminate the bias of the deletion scheme in Fig. 1a, we also tested if other 5-mer
peptides encompassing the SpT motif bind to Plk1 efficiently. LHSpTA, lacking the N-
terminal Pro but bearing the C-terminal Ala, bound to Plk1 almost as efficiently as PLHSpT
(Fig. 1b, left). However, HSpTAI, lacking both Pro and Leu but instead bearing two
additional C-terminal residues following the SpT motif, bound to Plk1 only weakly (Fig. 1b,
right), thus underlining the importance of the Leu-3 residue in the absence of the Pro-4
residue (see Supplementary Fig. 4 for molecular-level details). Among the 4-mers, both
LHSpT and HSpTA bound to Plk1 better than SpTAI (Fig. 1c). Comparative binding studies
showed that the binding affinity of a short form of the previously characterized optimal
PBD-binding peptide (MQSpTPL)13 is similar to that of the analogous p-T78 peptide
(LHSpTAI) (Fig. 1d).
A specific and high affinity binding between minimal p-T78 peptide and the Plk1 PBD
Next, we tested the specificity of minimal p-T78 peptides against Plk1 PBD. The results
showed that, similar to the initial 14-mer peptide, minimal p-T78 peptides precipitated Plk1
from cellular lysates containing similar levels of Plk1, Plk2, and Plk3 (Fig. 2a and
Supplementary Fig. 1b). In contrast, the 6-mer optimal MQSpTPL peptide precipitated Plk2
with ~27% efficiency of Plk1 precipitation (Fig. 2a), suggesting that it possesses a
significantly lower Plk1 specificity than PLHSpT. Consistently, MQSpTPL, but not the p-
T78 peptides, also precipitated Plk2 from the lysates expressing Plk2 alone (Supplementary
Fig. 1c). Remarkably, although much shorter than the initial 14-mer peptide, a minimal p-
T78 peptide, PLHSpT, exhibited an undiminished Plk1 specificity and precipitated Plk1 as
the only major binding protein from total cellular lysates (Fig. 2b). Another 5-mer,
LHSpTA, displayed a similar but somewhat reduced level of Plk1 affinity (Fig. 2b). These
results suggest that elements critical for Plk1-binding affinity and specificity reside within
these minimal sequences. Furthermore, PLHSpT efficiently bound to GST-fused PBD
(GST-PBD), but not to the respective GST-PBD(H538A, K540A) phosphate pincer mutant
(Fig. 2c), indicating that an intact phosphoepitope-binding module is required for the
interaction.
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Next, we carried out isothermal titration calorimetry analyses with recombinant Plk1 PBD
and quantified the binding parameters of the minimal p-T78 peptides. Among them, a 5-mer
PLHSpT mediated the best binding contacts with the PBD (ΔH = −14.5 kcal/mol) (Fig. 2d),
although it exhibited an equivalent binding affinity overall (Kd ~ 0.45 μM) with another 5-
mer, LHSpTA. Under the same conditions, the synthetic optimal 6-mer peptide, MQSpTPL,
bound to PBD with a Kd of 0.534 μM (Table 1). Two other 6-mer peptides (PLHSpTA and
LHSpTAI) displayed slightly higher affinities than the 5-mer peptides, whereas 4-mers
(LHSpT and HSpTA) exhibited much lower affinities (Table 1).
To test the specificity of the above peptides, we then conducted calorimetry binding
experiments with recombinant Plk2 PBD. Saturable binding was not observed in all cases
and, as a result of the lack of a binding curve, values for binding enthalpy or binding affinity
could not be extrapolated. However, a clear difference in the initial heats of interaction of
the peptides was observed above the limits of detection (1 kcal/mol) of the instrument. The
two minimal p-T78 peptides, PLHSpT and LHSpTA, exhibited virtually no interactions with
Plk2 (only baseline heats were detected), whereas MQSpTPL titrated into Plk2 PBD
produced initial heats of − 1.68 kcal/mol (Table 2). These results corroborate the specificity
of the minimal p-T78 peptides for Plk1 over Plk2.
p-T78 peptide disrupts the PBD-Cdc25C interaction
Next, we examined whether the minimal p-T78 peptides have the capacity to interfere with
the interaction between Plk1 PBD and its physiological binding target, phospho-Cdc25C (p-
Cdc25C). In agreement with the previous finding, GST-PBD precipitated p-Cdc25C, but not
the unphosphorylated form, from mitotic HeLa lysates13 (Supplementary Fig. 2a). Addition
of PLHSpT, but not the respective non-phosphopeptide, into the lysates disrupted the pre-
formed PBD-p-Cdc25C complex in both a phospho- and concentration-dependent manner
(Supplementary Fig. 2b). In a separate experiment, LHSpTA disrupted the pre-formed PBD-
p-Cdc25C complex nearly as efficiently as PLHSpT, whereas both LHSpT and HSpTA
disrupted the complex weakly (Fig. 2e). Furthermore, PLHSpT, but not the respective non-
phospho form, disrupted the in vivo Plk1-p-Cdc25C interaction (Fig. 2f). Thus, p-T78
peptides inhibit the interaction between the PBD and its binding targets by competitively
binding to the PBD.
The binding nature of the Plk1 PBD
To investigate the binding nature of the minimal peptides to the PBD, the crystal structures
of the Plk1 PBD in complex with the phosphopeptides PLHSpT (hereon referred to as
PBDPL) and PPHSpT (PBDPP; to examine the importance of the N-terminal residue for the
interaction) were solved at 1.7 Å and at 2.3 Å resolution, respectively (Fig. 3a,b and Table
3). Additionally, we attempted to crystallize a complex by mixing the PBD (without
phosphopeptide) and the kinase domain, each expressed and purified separately. However,
the kinase domain precipitated and only the PBD was found in a diffraction quality crystal.
This novel crystal form contained two PBD molecules per asymmetric unit, referred to as
PBDS+G (with sulfate and glycerol) and PBDS (with sulfate only) for chains A and B,
respectively (Fig. 3a). We found several strong peaks of positive difference density in the |
Fo|−|Fc| maps for PBDPL, PBDS+G and PBDS, which could not be interpreted as water
molecules. These peaks were modeled as sulfate, glycerol, and ethylene glycol molecules.
PBDPL contained a glycerol molecule in the phosphopeptide-binding cleft (Fig. 3a,b),
occupying a cavity formed by the phosphopeptide, two water molecules, and PBD. The
three hydroxyl groups of this glycerol molecule were involved in hydrogen bonding with the
backbone carbonyls of the phosphopeptide and PBD, the phosphate group of p-Thr, and one
of the water molecules. PBDS+G and PBDS contained a sulfate anion in the same pocket
(Fig. 3a), in the region normally occupied by the phosphate of p-Thr. The choice of
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modeling the density in this pocket as sulfate instead of phosphate stemmed from the
presence of 0.3 M lithium sulfate in the crystallization media. PBDS+G contained a glycerol
molecule in the phosphopeptide-binding cleft (Fig. 3a). This glycerol molecule was located
at the − 1 position, normally occupied by the Ser residue when a phosphopeptide is in the
binding cleft (Fig. 3a). The L2 loop in PBDS was much less ordered than in the PBDS+G
structure. Analysis of contacts with symmetry-related molecules showed that this difference
in the degree of order observed in the L2 region is likely caused by crystal packing.
The role of the N-terminal residues of p-T78 peptide for Plk1 binding affinity and specificity
Inspection of the structure of the PLHSpT-PBD complex revealed that, in addition to the
previously described SpT-dependent interactions12,13, the N-terminal Pro residue is crucial
for providing additional affinity to the PBD binding by engaging in two discrete yet
interconnected interactions. The carbonyl oxygen of the N-terminal Pro residue was in polar
contact (i. e., hydrogen-bonding) with the guanidinium moiety of Arg516, while the
pyrrolidine ring of the Pro residue enhanced the interaction by docking into a shallow
hydrophobic pocket generated by the surrounding Trp414 and Phe535 (Fig. 3a,b). The
importance of the latter interaction with the Pro-binding pocket was manifest by the
observation that LHSpT, which can still form the polar contact with Arg516 through the
carbonyl oxygen N-terminal to the Leu-3 residue, exhibited ~50-fold weaker binding than
PLHSpT (Table 1).
The critical role of the N-terminal Pro residue in PBD binding was directly demonstrated in
experiments with PPHSpT. Here, the N-terminal Pro at the − 4 position of PPHSpT was
flipped out of the Pro-binding pocket and was unable to generate the polar contact and
hydrophobic interactions because the Pro-3 residue locks the backbone of the
phosphopeptide in a conformation opposite to that of PLHSpT (Fig. 3c). Consequently,
PPHSpT exhibited a drastically diminished (20-fold) binding affinity to Plk1 (Fig. 3d).
Moreover, MLHSpT, bearing Met-4 instead of Pro-4, displayed a greatly diminished level of
Plk1 binding (Fig. 3e), further highlighting the importance of the Pro-4 residue in stably
binding into the pocket. Consistent with these observations, the Pro-4 residue in
PMQSpTPL docked into the Pro-binding pocket13 (Fig. 3c), while, in the absence of the N-
terminal Pro-4, the side chain of the free (i. e., unacetylated) N-terminal Met-3 in MQSpTPL
extended into the pocket12 (Fig. 3c).
It is noteworthy that LHSpTA also exhibited a high level of Plk1 PBD binding affinity and
specificity even in the absence of the Pro-4 residue (Figs. 2a,b,d). Analyses of the crystal
structure of the Plk1 PBD in complex with LHSpTA (PBDLH, Table 3) revealed that, similar
to the Leu-3 of PLHSpT, the N-terminal Leu-3 side chain of LHSpTA was directed into an
intramolecular cavity and did not appear to be involved in interactions with surrounding
PBD residues (Supplementary Fig. 3). The N-terminal acetyl carbonyl of LHSpTA was in
polar contact with Arg516, thus substituting the interaction engaged by the carbonyl oxygen
of the Pro-4 of PLHSpT. Since Plk2 and Plk3 possess a Lys residue at the position
analogous to the Plk1 Arg516, the polar contact observed in the two Plk1-specific peptides,
PLHSpT and LHSpTA, is likely one of the major determinants of Plk1 PBD specificity.
Apart from the phosphopeptide backbone region of the Leu-3 as mentioned above, the weak
electron density (2|Fo|−|Fc|) observed in the PBDPL structure (Supplementary Fig. 4)
suggested that the Leu side chain region is disordered and may not be involved in
interactions with PBD. However, mutation of the Leu-3 of PLHSpT to Ala greatly
diminished the level of Plk1 binding, while the mutation to Gln did not alter the Plk1 affinity
(Fig. 3d).
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Next, the importance of the His-2 residue for Plk1 specificity was examined. In the crystal
structure, the side chain of the His-2 residue did not directly mediate contacts with PBD
residues (Fig. 3a,b). Strikingly, mutation of the His-2 to Gln substantially increased (24-
fold) the level of Plk2 binding (Fig. 3d). In calorimetry experiments, titration of the PLQSpT
mutant into Plk2 PBD produced initial heats of interaction on the order of − 1.1 kcal/mol as
compared to virtually baseline heats for the parent PLHSpT (Table 2), suggesting that the
mutant peptide mediates binding contacts with Plk2 PBD, whereas the parent peptide is
selective only for Plk1 PBD.
Our results suggest that the N-terminal Pro-Leu motif at the − 4 and − 3 positions is crucial
for high affinity and specificity interactions with Plk1 PBD, while the His residue at the − 2
position is important to assure an additional layer of Plk1 specificity (Fig. 3f). These
findings explain in part why MQSpTPL, bearing the N-terminal Met for the Pro-binding
pocket and lacking the critical His-2 residue, exhibits a low Plk1 specificity. In addition, the
T78 residue in PBIP1 is followed by Ala in place of the commonly found Pro residue, thus
allowing a non-Pro-directed kinase such as Plk1 to phosphorylate the T78 residue (Fig. 3f).
Inhibition of the function of the Plk1 PBD by a p-T78 mimetic peptide
The PBD-dependent interactions with various S-p-S/T-containing targets are critical for
proper Plk1 localization. As expected, acute inhibition of Cdc2, one of the major kinases
that prime the PBD-binding sites, drastically diminished the level of Plk1 localization to the
centrosomes and kinetochores in prometaphase cells (Supplementary Fig. 5). This
observation prompted us to test whether the minimal p-T78 peptides can interfere with the
function of Plk1 by disrupting its localization in vivo. Consistent with the PBD pull-down
assays, PLHSpT, but not the respective non-phosphopeptide, efficiently inhibited the p-T78-
dependent PBD interaction in vitro, while LHSpTA inhibited the PBD at a moderately
reduced level (Supplementary Fig. 6). Since the phosphate group of the T78 residue is
strictly required for the PBD binding but is susceptible to dephosphorylation by intracellular
phosphatases, we therefore synthesized phosphatase-resistant p-Thr mimetic, (2S,3R)-2-
amino-3-methyl-4-phosphonobutyric acid (Pmab), in protected form and incorporated it into
peptides in place of the p-Thr residue (Fig. 4a). The bead-immobilized PLHS-Pmab
precipitated Plk1, but not Plk2 or Plk3, from mitotic HeLa lysates as efficiently as the
respective PLHSpT peptide (Fig. 4a,b). As expected if the binding were PBD-dependent, a
mutation of the invariably required Ser-1 residue to Ala {PLHA-Pmab; in short,
Pmab(S77A)} abolished the Plk1 binding. Furthermore, the PLHS-Pmab peptide, but not the
respective Pmab(S77A) mutant, efficiently interfered with p-T78-dependent Plk1 PBD
interaction (Fig. 4c).
To examine the effect of the Pmab-containing mimetic peptide in vivo and to overcome poor
membrane permeability of a negatively charged peptide, we performed microinjection
studies using HeLa cells released from an S phase block. As expected if the function of Plk1
PBD were inhibited, the Pmab peptide, but not the Pmab(S77A) or non-phospho T78
peptide, induced a mitotic arrest in ~60% of the microinjected population. Reminiscent of
the phenotype associated with the loss of PBD function10,18, ~25% of the arrested
population (n > 180 cells) exhibited a chromosome congression defect (Fig. 4d–f). Due to
the increasing level of apoptotic cell death following a prolonged mitotic block, the total
numbers of arrested cells began to shrink at later time points (Fig. 4e). Consistent with these
observations, the Pmab peptide, but not the Pmab(S77A) or non-phospho T78 peptide,
interfered with Plk1 localization at the centrosomes and kinetochores and diminished Plk1
fluorescence signals (Fig. 4f,g) to a level similar to that observed after the treatment of the
Cdc2 inhibitor, BMI-1026 (Supplementary Fig. 5). Although not as efficient as the PLHS-
Pmab peptide, another type of a F2Pmab-containing PLHS-F2Pmab-A, but not the respective
F2Pmab(S77A) mutant, precipitated Plk1 (Supplementary Fig. 7a), and, as such, induced
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Plk1 delocalization and chromosome misalignment that led to mitotic arrest and apoptotic
cell death (Supplementary Fig. 7b–f). These results demonstrate that inhibition of the PBD
by the p-T78 mimetic peptide is sufficient to interfere with subcellular localization and
mitotic functions of Plk1.
DISCUSSION
Plk1 overexpression is closely associated with tumorigenesis in a wide range of human
cancers. It is also associated with aggressive disease stage and poor patient survival in
various types of cancers5, suggesting that Plk1 is an attractive target for therapeutic
intervention against human cancers. Over the years, efforts have been made to generate anti-
Plk1 inhibitors, resulting in several compounds (BI 2536, GSK Compound 1, Cyclapolin 1,
DAP81, and TAL) developed to competitively inhibit the kinase activity of Plk15. However,
largely because of the structural similarities among the catalytic domains of all Plks and
other related kinases, it has been difficult to generate Plk1-specific inhibitors. Since the non-
catalytic PBD is found only in the members of the Plk subfamily, development of novel
inhibitors that target the PBD of Plk1 may prove to be an alternative strategy for selectively
targeting Plk1.
While conducting studies on the interaction between Plk1 and its physiological binding
target PBIP1, we identified minimal phosphopeptides derived from the T78 region of PBIP1
that exhibit a high level of affinity and specificity for the Plk1 PBD. Similar to the defects
associated with the expression of a dominant-negative PBD10,18, inhibition of the Plk1
PBD function by non-hydrolyzable p-T78 mimetic peptides induced a chromosome
congression defect that leads to mitotic arrest and apoptotic cell death. Since interference
with Plk1 function induces apoptosis in most tumor cells but not in normal cells5, these
findings suggest that inhibition of the PBD function is sufficient to interfere with tumor cell
proliferation. Furthermore, our results shown here provide the proof-of-principle that
specific inhibition of Plk1 PBD is achievable by small mimetic peptides or their relevant
compounds.
It has been demonstrated that SpT-dependent electrostatic interactions are critical for the
binding of optimal peptides (PMQSpTPL and MQSpTPL) to the Plk1 PBD12,13.
Comparative in vitro binding studies and analyses of the phosphopeptide-binding pockets of
PBDS+G and PBDS with PBDPL, PBDPP, and PBDLH revealed that, in addition to the SpT
motif of the phosphopeptide that acts as a high affinity anchor, the N-terminal residues
provide additional binding affinity and specificity to the Plk1 PBD through at least three
distinct interactions. First, the polar contact between the carbonyl oxygen N-terminal to the
Leu-3 of PLHSpT or LHSpTA and the guanidinium moiety of Arg516 of Plk1 PBD
provides a molecular basis for a high affinity and specificity interaction. Unlike Plk1, both
Plk2 and Plk3 possess a Lys residue (Lys607 and Lys568, respectively) at the position
analogous to the Plk1 Arg516. Second, docking of the N-terminal Pro-4 side chain into the
pocket generated by the surrounding Trp414 and Phe535 offers additional affinity and likely
another layer of specificity to the interaction. The PBDs from both Plk2 and Plk3 possess
Lys and Tyr residues at positions corresponding to the Plk1 Arg516 and Phe535 residues,
respectively, and, as a consequence, may fail to generate as favorable an environment to
accommodate the N-terminal Pro residue. Third, mutational analyses of PLHSpT suggest
that the His-2 residue is also critical in determining Plk1 PBD specificity. Since the NΔ1 of
His-2 was involved in a hydrogen bond with the carbonyl oxygen of Ser-1, one possibility is
that the hydrogen bond between these two residues is important for conferring Plk1
specificity. Alternatively, the presence of a Gln residue at the − 2 position could be crucial
for strong Plk2-mediated interactions.
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Besides each amino acid residue of the p-T78 peptide involved in defining the Plk1 PBD
binding, the positions of the glycerol in the neighboring pocket and the network of water
molecules that mediate contacts between the phosphopeptide and the PBD suggest that both
the glycerol and the network of water molecules surrounding the phosphopeptide could be
important elements of the PBD recognition by phosphopeptides. Furthermore, the structures
of the PBDS+G, PBDS, and PBDPL were remarkably similar, hinting that the glycerol
molecule and the sulfate anion that occupy the phosphopeptide-binding cleft may mimic the
role of the SpT dipeptide.
In conclusion, our results provided here demonstrate that the Plk1 PBD-binding pocket
accommodates (i) the core SpT motif, (ii) the N-terminal hydrophobic residue, (iii) glycerol,
and (iv) a network of contacting water molecules. A combination of some or all of these four
elements could be potentially used for targeted drug design. Better understanding of the
PBD interaction as well as further isolation and development of PBD-binding agents would
greatly facilitate the discovery of a new class of Plk1-specific anti-cancer therapeutic agents.
METHODS
Synthesis of peptides
The list of peptides used in this study is shown in Supplementary Table 1. We synthesized
the peptides using a 9-Fluorenylmethoxycarbony (Fmoc)-based solid-phase method on Rink
amide resin (0.36 mmol g−1) (Novabiochem, San Diego, CA) at the 0.1 mmol scale. Briefly,
Fmoc-protected amino acids (2.5-fold molar excess) were sequentially condensed using 0.25
mmol of N,N′-diisopropylcarbodiimide-N-hydroxybenzotriazole dissolved in
dimethylformamide. Fmoc deprotection was achieved by 20% v/v piperidine/N-
methylpyrrolidinone. The synthesis of protected (2S,3R)-2-amino-3-methyl-4-
phosphonobutyric acid (Pmab) and its incorporation into peptides will be reported
separately. For peptide-based pull-down assays, peptides bearing the N-terminal Cys-(CH2)6
linkers (1 mM stock) were cross-linked to the beads using SulfoLink Coupling gel (Pierce,
Rockford, IL).
Peptide pull-down, GST-PBD pull-down, and PBD-binding inhibition assays
Peptide and GST-PBD pull-down assays were performed as described previously14. An
ELISA-based PBD-binding inhibition assay was carried out using an immobilized p-T78
peptide and cellular lysates expressing HA-EGFP-Plk1. Further details are described in the
Online Supplemental Materials.
Isothermal titration calorimetry analyses
Calorimetric titrations were carried out using purified recombinant PBDs (for Plk1 and
Plk2) from bacterial cells and the indicated peptides. Further details are presented in Online
Supplemental Materials.
Cloning, Protein Expression, and Purification
Details of PBD construction, expression, and purification are described in Online
Supplemental Materials.
Crystallization, Data Collection, and Refinement for PBDPL and PBDPP
All initial crystallization screens for the Plk1 PBD-PLHSpT complex were performed on an
Art Robbins Phoenix Liquid Handling System using Index (Hampton Research, Aliso Viejo,
CA) and PEGs (Qiagen, Valencia, CA) crystallization kits. All subsequent crystals were
grown using the hanging-drop vapor diffusion method at room temperature. PBD and the
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kinase domain of Plk1 were concentrated to ~30 mg/ml in buffer A (20 mM Tris-Cl, pH 8.0,
500 mM NaCl, 3 mM DTT). The phosphopeptide Ac-PLHSpT was dissolved in buffer A.
The phosphopeptide and PBD were added in 2:1 stoichiometric ratio, respectively, and the
final concentration was adjusted to ~15 mg/ml. Crystals of this complex were grown by
adding 1 μl of this complex to 1 μl of well solution (0.2 M di-potassium phosphate, 20% w/
v PEG 3350). The complex between PBD and kinase domain was formed similarly using a
1:1 stoichiometric ratio, and 0.2 M lithium sulfate monohydrate, 0.1 M Bis-Tris, pH 5.5,
25% w/v PEG 3350 as the well solution. Crystals formed within one week and were soaked
for 5 minutes in mother liquor constituted with 20% v/v glycerol prior to flash-freezing in
liquid nitrogen. The complex of PBD and Ac-PLHSpT crystallized in the space group
P212121 (a = 35.19 Å, b = 65.76 Å, c = 104.11 Å). The kinase domain of Plk1 precipitated
and PBD crystallized in the space group P21 (a = 35.29 Å, b = 102.29 Å, c = 68.55 Å, β =
93.24°).
Crystals of the Plk1 PBD-PPHSpT complex were obtained in a similar fashion using a well
solution of 0.1 M MES buffer (pH 6.0) containing 15% w/v PEG 3350. The crystals were
soaked for 5 minutes in the mother liquor constituted with 15% v/v glycerol, 10 mM DTT
and 2 mM of the phosphopeptide Ac-PPHSpT prior to freezing in liquid nitrogen. This
complex crystallized in the space group P212121 (a = 35.44 Å, b = 66.50 Å, c = 105.82 Å).
All datawere collected at 100K. The data for PBD, and PBD in complex with Ac-PLHSpT
were collected at the SER-CAT beamline 22-ID,at the Advanced Photon Source (APS), on a
MAR 300CCD detector. The data for the complex of PBD and Ac-PPHSpT were collected
at APS beamline 24-ID-C at 100 K. All data were processed and scaled using the HKL2000
package19. Phasing of the data was done by molecular replacement using a previously
published structure (PDB ID: 1UMW). The structures were refined independently of each
other with the program REFMAC520 and CNS1.121. Model building was performed using
Coot22 and XtalView23 (Table 3).
Cell culture, microinjection, and confocal microscopy
Detailed information on cell culture, microinjection and confocal microscopic procedures
are provided in Online Supplemental Materials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Minimization of PBIP1 p-T78 peptide that binds to Plk1. (a–c) Various lengths of N-
terminal Cys-(CH2)6-fused T78 peptides were cross-linked to the beads (a) and then tested
for their ability to bind to Plk1. The Ser residue (blue) in (a, right) indicates the invariable
S77 residue critical for PBD binding. For comparison, a shortened form of the synthetic
peptide optimized for Plk1 PBD binding (MQSpTPL)13 was included. (d) A 6-mer T78
peptide (LHSpTAI) analogous to the synthetic optimal peptide (MQSpTPL) was tested for
Plk1 binding. Numbers indicate the efficiency of Plk1 precipitation by each peptide relative
to the Plk1 signal in the input.
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Fig. 2.
Minimal p-T78 peptides specifically bind to Plk1 with a high affinity. (a) HeLa lysates
expressing the kinase-inactive Flag-Plk1(K82M), Flag-Plk2(K108M), or Flag-Plk3(K52R)
were mixed before incubating with the bead-bound T78 peptides or synthetic optimal
peptide (MQSpTPL) as indicated. Precipitates were immunoblotted with anti-Flag antibody.
Because of the distinct binding nature of Plk4 PBD, Plk4 was not tested. Numbers indicate
the fraction of Plk2 over Plk1 bound to the peptide. Arrows indicate Flag-Plk1, 2, 3 proteins.
(b) Mitotic HeLa lysates were incubated with the indicated bead-bound peptides. Co-
precipitating proteins were analyzed by silver staining. Arrows, Plk1 precipitated with p-T78
peptides. (c) Soluble control GST, GST-PBD, or GST-PBD(H538A K540M) was incubated
with the indicated T78 peptides immobilized to the beads. Bound proteins were
immunoblotted with anti-GST antibody. (d) Isothermal titration calorimetry for the p-T78
peptides was performed using purified Plk1 PBD. Representative calorimetric isotherms for
the binding of two 5-mers (PLHSpT and LHSpTA) to the PBD are shown. The solid lines
represent fits to the data. The overall H (kcal/mol) is easily observed as the difference
between the pre- and the post-binding baselines extrapolated along the y-axis. (e) Mitotic
HeLa lysates were pre-incubated with bead-bound GST-PBD for 1.5 h prior to the addition
of the indicated peptides. After another 1.5 h incubation, GST-PBD-binding proteins were
precipitated and analyzed as in (a). Detection of GST-PBD in the anti-Cdc25C blot is the
result of the previous anti-GST immunoblotting. Numbers indicate relative efficiency of p-
Cdc25C pull-down by GST-PBD. (f) Mitotic HeLa lysates were treated with the indicated
peptide prior to immunoprecipitation with either control IgG or anti-Plk1 antibody.
Immunoprecipitates were blotted with the indicated antibodies. Asterisk, a cross-reacting
protein.
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Fig. 3.
The nature of PBD binding and specificity. (a) Superposition of the phosphopeptide-binding
pockets of PBDPL, PBDPP, PBDS+G, and PBDS. PBD is drawn in grey. PLHSpT is in green
and its associated glycerol molecule is in yellow. PPHSpT is drawn in cyan. The glycerol
molecule (two half-occupancy conformations at the Ser-1 position) of PBDS+G is drawn in
magenta. The two sulfate anions of PBDS+G and PBDS are drawn with the sulfur atoms in
black and oxygen atoms in red. The differences in the exact positions of sulfate and
phosphate groups could be due to the fact that the sulfate is a free anion, whereas the
phosphate is covalently linked to the phosphopeptide. PDB ID for PBDPL, 3HIK; PDB ID
for PBDPP, 3C5L; PDB ID for PBDS+G and PBDS, 3HIH. (b) The PBD residues involved in
binding of PLHSpT are labeled and shown in cyan. All water molecules that form an
interface between the phosphopeptide and PBD are drawn in red mesh. (c) Superposition of
PLHSpT (green), PPHSpT (cyan), MQSpTPL (magenta), and PMQSpTPL (grey). (d,e) The
mixture of HeLa lysates expressing the kinase-inactive Flag-Plk1(K82M), Flag-
Plk2(K108M), or Flag-Plk3(K52R) was subjected to pull-down assays as in Fig. 2a with the
indicated 5-mer wild-type (PLHSpT) and mutants cross-linked to the beads. The respective
non-phospho-T78 peptide (PLHST) was used as a control. The numbers at the top of the blot
indicate the relative efficiency of Plk2 precipitation, whereas the numbers at the bottom
denote the relative efficiency of Plk1 precipitation. (f) Illustration depicting the nature of the
interactions between the SpT-containing peptides and the Plk1 PBD. Alignment of minimal
p-T78 peptides (PLHST and LHSTA) and synthetic optimal peptides (PMQSTPL and
MQSTPL) showed that, in addition to the critical SpT motif, the N-terminal Pro-4 and
Met-3 residues are important to stabilize the interactions by docking into a hydrophobic core
surrounded by the Trp414, Phe535 and Arg516 residues in Plk1 PBD. The His-2 residue is
important for Plk1 specificity since substitution of Gln for His enhances Plk2 binding. The
Ala+1 or Pro+1 residue is central for guiding a priming kinase to phosphorylate the Thr
residue.
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Fig. 4.
A 5-mer p-T78 mimetic peptide (PLHS-Pmab) induces mitotic arrest by specifically
inhibiting Plk1 localization. (a) Illustration of a nonhydrolyzable p-Thr derivative, Pmab
(Top), used for the synthesis of mimetic peptides. The indicated, bead-immobilized,
peptides were incubated with mitotic HeLa lysates in the presence of phosphatase inhibitors,
and then analyzed as in Fig. 1a. T78, C-(CH2)6-PLHST; p-T78, C-(CH2)6-PLHSpT; Pmab,
C-(CH2)6-PLHS-Pmab; Pmab(S77A), C-(CH2)6-PLHA-Pmab. (b) The same peptides used
in (a) were incubated with the mixture of HeLa lysates expressing the kinase-inactive Flag-
Plk1(K82M), Flag-Plk2(K108M), or Flag-Plk3(K52R). Bead-associated proteins were
analyzed as in Fig. 2a. The membrane was stained with Coomassie (CBB). (c) To
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quantitatively determine the efficiency of PBD-binding inhibition by the indicated peptides,
an ELISA-based inhibition assay was performed in the presence of various amounts of the
indicated competitor peptides (see Methods for details). (d,e) HeLa cells arrested in S phase
by thymidine treatment were released into fresh medium. Two hours after release, all the
cells (~150 cells) in a single grid were microinjected with a mixture containing 2.5 mM of
the indicated peptide and 30 ng/μl of pEGFP-C1 vector (to visualize the injected cells), and
then further incubated. Cells were photographed 12 h after releasing from the S phase block
(d). To monitor cell cycle progression, the percentages of mitotic cells were quantified at the
indicated time points (e). Bars, standard deviation. (f) Cells microinjected similarly as in (d)
were fixed and immunostained with anti-Plk1 antibody. Images were acquired from EGFP-
positive cells. Asterisks, centrosome-localized Plk1 signals; arrowed brackets, kinetochore-
localized Plk1 signals; arrows, misaligned chromosomes. (g) Fluorescence intensities for
centrosome-localized (n > 20 centrosomes) or kinetochore-localized (n > 45 kinetochores,
average of 6 kinetochores per cell) anti-Plk1 signals in (f) were quantified as described in
the Methods. Bars (red), the averages of relative fluorescence intensities.
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Table 1
A comparison of the thermodynamic binding parameters of minimal Plk1-binding peptides
Peptides Kd (μM) ΔH (kcal/mol) ΔS (cal/mol/K) ΔG (kcal/mol)
MQSpTPL 0.534 ± 0.230 − 10.01 ± 5.53 − 5.24 ± 1.85 − 8.55 ± 0.57
PLHSpTA 0.262 ± 0.130 − 11.60 ± 3.53 − 8.83 ± 1.18 − 8.97 ± 0.27
LHSpTAI 0.247 ± 0.050 − 11.30 ± 2.23 − 7.54 ± 0.75 − 9.00 ± 0.11
LHSpTA 0.447 ± 0.110 − 9.90 ± 0.40 − 4.19 ± 1.33 − 8.65 ± 0.14
PLHSpT 0.445 ± 0.180 − 14.50 ± 5.01 − 19.71 ± 3.38 − 8.66 ± 0.49
LHSpT 22.100 ± 0.950 − 6.29 ± 2.22 − 0.20 ± 0.07 − 6.35 ± 0.60
HSpTA 19.500 ± 1.700 − 3.82 ± 0.25 − 8.70 ± 0.85 − 6.42 ± 0.05
LHSTAI no binding no binding no binding no binding
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Table 3
Data collection and refinement statistics (molecular replacement)
PBDPL PBDS and PBDS+G PBDPP PBDLH
Data collection
Space group P212121 P21 P212121 P21
Cell dimensions
 a, b, c (Å) 35.2, 65.8, 104.1 33.3, 102.3, 68.5 35.4, 66.5, 105.8 38.3, 62.4, 46.6
 α, β, γ (°) 90.0, 90.0, 90.0 90.0, 93.2, 90.0 90, 90, 90 90, 94.1, 90
Resolution (Å) 50.0–1.77 (1.86–1.77) 30.0–1.70 (1.76–1.70) 33.6–2.33 (2.41–2.33) * 25.0–1.58 (1.64–1.58)
Rsym or Rmerge 0.051 (0.349) 0.055 (0.259) 0.051 (0.268) 0.042 (0.172)
I/σI 22.6 (3.6) 23.1 (2.9) 27.3 (4.9) 32.1 (8.6)
Completeness (%) 96.6 (85.0) 98.4 (85.8) 97.4 (86.5) 96.4 (94.2)
Redundancy 4.4 (4.2) 4.8 (2.9) 6.2 (5.0) 4.7 (4.5)
Refinement
Resolution (Å) 50.0–1.77 30.0–1.70 33.6 – 2.33 25–1.58
No. reflections 22482 48194 10186 28941
Rwork/Rfree 0.205/0.237 0.186/0.219 0.246/0.293 0.1887/0.2289
No. atoms
 Protein 1795 3504 1768 1895
 Ligand/ion 64 42 75
 Water 122 327 35 262
B-factors
 Protein 33.7 20.4 41.7 21.7
 Ligand/ion 36.5 36.8 39.3 18.5
 Water 42.6 33.0 37.2 30.0
R.m.s. deviations
 Bond lengths (Å) 0.018 0.016 0.008 0.012
 Bond angles (°) 1.786 1.551 1.30 1.163
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